Galectin Therapeutics Inc. (GALT) Key Metrics
GALT valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $365.1M
- Enterprise value
- $545.7M
- P/E (TTM)
- —
- Forward P/E
- 4.5
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 207.7 10-yr median 12.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.38
GALT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGALT valuation Price multiples at each fiscal year-end price.
Free cash flow yield+43.0 pts
−9.0%
2025 · hover or tap a bar for each year
20162025
GALT returns How much profit the business earns on the capital it uses.
Return on assets+39.4 pts
−166.6%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
GALT per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.48
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.37
2025 · hover or tap a bar for each year
20162025
Book value per share
−$1.97
2025 · hover or tap a bar for each year
20162025
Dividends per share+47.9%
$0.00
2025 · hover or tap a bar for each year
20162025
Shares outstanding+2.6%
63.9M
2025 · hover or tap a bar for each year
20162025
GALT financial health Debt, liquidity and how easily interest is covered.
Net debt+$24.9M
$116.0M
2025 · hover or tap a bar for each year
20162025
Current ratio+396.8%
2.42
2025 · hover or tap a bar for each year
20162025
Interest coverage
-2.7
2025 · hover or tap a bar for each year
20162025
Debt / assets+12.8%
6.85
2025 · hover or tap a bar for each year
20162025
GALT valuation history
Fiscal year-endToday10-year median
GALT returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GALT debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GALT cash returned to shareholders
DividendsBuybacksFree cash flow
GALT price vs earnings per share
Share price at year-endEPS (right axis)
GALT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $265.8M | $80.4M | $99.9M | $67.1M | $121.2M | $127.7M | $149.4M | $135.2M | $118.6M | $28.6M |
| Enterprise value | $381.9M | $171.5M | $146.0M | $88.4M | $110.6M | $100.6M | $102.0M | $126.9M | $115.6M | $13.3M |
| Price / book | — | — | — | — | 46.3 | 5.3 | 3.3 | 19.6 | 99.4 | 2.4 |
| Earnings yield | −11.6% | −58.5% | −41.1% | −57.8% | −25.2% | −18.4% | −8.9% | −10.3% | −13.7% | −74.9% |
| Free cash flow yield | −9.0% | −52.0% | −33.0% | −46.3% | −20.1% | −16.1% | −7.3% | −7.5% | −13.4% | −57.3% |
| Dividend yield | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.3% | 0.7% | 1.0% | 2.6% |
| Shareholder yield (dividends + buybacks) | 0.1% | 0.1% | 0.1% | 0.1% | 24.9% | 0.1% | 0.3% | 0.7% | 1.0% | 2.6% |
| Share price at fiscal year-end | $4.16 | $1.29 | $1.66 | $1.13 | $2.07 | $2.24 | $2.86 | $3.43 | $3.34 | $0.98 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.48 | −$0.76 | −$0.68 | −$0.65 | −$0.52 | −$0.41 | −$0.25 | −$0.35 | −$0.46 | −$0.73 |
| Operating cash flow per share | −$0.37 | −$0.67 | −$0.55 | −$0.52 | −$0.42 | −$0.36 | −$0.21 | −$0.26 | −$0.45 | −$0.56 |
| Free cash flow per share | −$0.37 | −$0.67 | −$0.55 | −$0.52 | −$0.42 | −$0.36 | −$0.21 | −$0.26 | −$0.45 | −$0.56 |
| Cash per share | $0.28 | $0.24 | $0.43 | $0.31 | $0.68 | $0.48 | $0.91 | $0.21 | $0.09 | $0.53 |
| Book value per share | −$1.97 | −$1.65 | −$1.00 | −$0.54 | $0.04 | $0.42 | $0.87 | $0.18 | $0.03 | $0.41 |
| Tangible book value per share | −$1.97 | −$1.65 | −$1.00 | −$0.54 | $0.04 | $0.42 | $0.87 | $0.18 | $0.03 | $0.41 |
| Dividends per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.02 | $0.03 | $0.03 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $2.09 | $1.71 | $1.19 | $0.67 | $0.50 | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Shares outstanding | 63.9M | 62.3M | 60.2M | 59.4M | 58.5M | 57.0M | 52.2M | 39.4M | 35.5M | 29.2M |
| Change in shares outstanding | +2.6% | +3.6% | +1.3% | +1.5% | +2.6% | +9.2% | +32.5% | +11.0% | +21.6% | +21.1% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −227.7% | −67.2% | −50.7% | −343.6% | −245.8% | −115.7% |
| Return on assets (ROA) | −166.6% | −205.9% | −166.0% | −122.9% | −85.5% | −60.1% | −46.3% | −211.1% | −162.7% | −101.6% |
| Return on tangible assets | −157.9% | −268.9% | −145.6% | −182.2% | −73.0% | −79.3% | −27.4% | −154.3% | −390.2% | −135.7% |
| Financial health | ||||||||||
| Total debt | $133.8M | $106.2M | $71.8M | $39.9M | $29.1M | $44,000 | $39,000 | — | $0 | $0 |
| Cash & short-term investments | $17.7M | $15.1M | $25.7M | $18.6M | $39.6M | $27.1M | $47.5M | $8.3M | $3.1M | $15.4M |
| Net debt | $116.0M | $91.1M | $46.1M | $21.3M | −$10.6M | −$27.1M | −$47.4M | −$8.3M | −$3.1M | −$15.4M |
| Debt / equity | — | — | — | — | 11.11 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Debt / assets | 6.85 | 6.07 | 2.55 | 1.87 | 0.69 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Current ratio | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 | 5.46 | 17.10 | 4.19 | 1.29 | 4.18 |
| Quick ratio | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 | 5.46 | 17.10 | 4.19 | 1.29 | 4.18 |
| Interest coverage | -2.7 | -7.7 | -13.6 | -37.1 | -61.7 | -269.5 | -154.5 | -40.5 | — | — |
| Working capital | $11.4M | −$18.2M | $12.0M | $7.5M | $32.8M | $24.1M | $45.4M | $6.7M | $851,000 | $12.0M |
| Invested capital | −$10.2M | −$11.9M | −$14.1M | −$10.9M | −$8.0M | −$2.9M | −$1.8M | −$1.4M | −$1.9M | −$3.3M |
| Tangible asset value | −$126.2M | −$103.1M | −$60.2M | −$32.2M | $2.6M | $24.2M | $45.6M | $6.9M | $1.2M | $12.0M |
| Net current asset value | −$126.3M | −$103.3M | −$60.7M | −$32.9M | $2.6M | $24.1M | $45.3M | $6.7M | $851,000 | $12.0M |
| Graham net-net per share | −$2.00 | −$1.69 | −$1.04 | −$0.59 | $0.01 | $0.38 | $0.85 | $0.16 | $0.00 | $0.40 |
| Capital allocation | ||||||||||
| Dividends paid | $138,000 | $91,000 | $120,000 | $97,000 | $171,000 | $137,000 | $394,000 | $915,000 | $1.2M | $741,000 |
| Share buybacks (net) | $0 | $0 | $0 | $0 | $30.0M | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||||||||
| Days payables outstanding | — | 59,618.3 | 57,078.3 | 32,479.3 | 13,785.4 | 14,970.1 | 10,209.6 | 165,162.5 | 277,035.0 | 35,405.0 |
| Payables turnover | — | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 | 0.04 | 0.00 | 0.00 | 0.01 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $4.5M | $6.0M | $5.2M | $2.8M | $1.5M | $1.5M | $979,000 | $452,500 | $759,000 | $679,000 |
| Average inventory | — | — | — | — | — | — | — | — | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from GALT's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GALT valuation and financial ratios
It ended the year with $133.8 million of debt and $17.7 million in cash and short-term investments, net debt of $116.0 million. It returned $0.1 million to shareholders: $0.1 million in dividends and $0 in share buybacks. The share count rose 118.7% from 29.2M to 63.9M over 9 years.
See the GALT income statement, the GALT chart for price history, or the GALT stock overview for the latest quote and news.
GALT key metrics FAQ
How much debt does Galectin Therapeutics have?
Galectin Therapeutics had total debt of $133.8 million at the end of fiscal 2025.
What is Galectin Therapeutics's dividend yield?
Galectin Therapeutics paid $0.1 million in dividends in fiscal 2025 ($0.00 per share), a payout ratio of —.
What is Galectin Therapeutics's free cash flow yield?
Galectin Therapeutics generated -$23.9 million of free cash flow in fiscal 2025, a free cash flow yield of −9.0% on its market value at year-end ($265.8 million).
What is Galectin Therapeutics's current ratio?
Galectin Therapeutics's current ratio was 2.42 at the end of fiscal 2025: current assets were 2.42 times current liabilities.